Nuclear factor κB decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model

Hepatology

Volumn 38, Issue 2, 2003, Pages 335-344

  Ogushi, Ichiro ^a   Iimuro, Yuji ^a   Seki, Ekihiro ^a   Son, Gakuhei ^a   Hirano, Tadamichi ^a   Hada, Toshikazu ^a   Tsutsui, Hiroko ^a   Nakanishi, Kenji ^a   Morishita, Ryuichi ^b   Kaneda, Yasufumi ^b   Fujimoto, Jiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; INFLAMMATORY CELL; KUPFFER CELL; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PORTAL VEIN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0042766886     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50298     Document Type: Article

References (52)

1. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. HEPATOLOGY 1995;21:240-252.
2. Mas A, Rodes J. Fulminant hepatic failure. Lancet 1997;349:1081-1085.
3. Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Gimson A, Casewell M. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. HEPATOLOGY 1990;11:49-53.
4. Williams R. Classification, etiology, and consideration of outcome in acute liver failure. Semin Liver Dis 1996;16:343-348.
5. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The system inflammatory response syndrome in acute liver failure. HEPATOLOGY 2000;32:734-739.
6. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med 1987;38:417-432.
7. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-1835.
8. Iimuro Y, Yamamoto M, Kohno H, Itakura J, Fujii H, Matsumoto Y. Blockade of liver macrophages by gadolinium chloride reduces lethality in endotoxemic rats-analysis of mechanisms of lethality in endotoxemia. J Leukoc Biol 1994;55:723-728.
9. Mochida S, Ohno A, Arai M, Tamatani T, Miyasaka M, Fujiwara K. Role of adhesion molecules in development of massive hepatic necrosis in rats. HEPATOLOGY 1996;23:320-328.
10. Arai M, Mochida S, Ohno A, Ogata I, Fujiwara K. Sinusoidal endothelial cell damage by activated macrophages in rat liver necrosis. Gastroenterology 1993;104:1466-1471.
11. Tsutsui H, Matsui K, Kawada N, Hyodo Y, Hayashi N, Okamura H, Higashino K, et al. IL-18 accounts for both TNF-α-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997;159:3961-3967.
12. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Haruka A, Tanimoto T, Torigoe K, et al. Cloning of a new cytokine that induces IFN-γ-production by T-cells. Nature 1995;378:88-91.
13. Heremans H, Van Damme J, Dillen C, Dijkmans R, Billiau A. Interferon γ, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med 1990;171:1853-1869.
14. Kobayashi M, Fitz L, Lyan M, Hewick RM, Clark SC, Chan S, Loudon R, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-845.
15. Sakao Y, Terada K, Tsutsui H, Kaisho T, Nomura F, Okamura H, Nakanishi K, et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int Immunol 1999;11:471-480.
16. Cross S, Halden NF, Lenardo MJ, Leonard WJ. Functionally distinct NFκB binding sites in the Ig kappa and IL-2 receptor alpha chain genes. Science 1989;244:466-469.
17. Finco TS, Baldwin AS. Mechanistic aspects of NFκB regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995;3:263-272.
18. Leonardo MJ, Baltimore D. NFκB: a pleiotropic activator of inducible and tissue specific gene control. Cell 1989;58:227-237.
19. Baeurle PA, Henkel T. Function and activation of NFκB in the immune system. Annu Rev Immunol 1994;12:141-179.
20. Sha WC, Liou H, Tuomanen E, Baltimore D. Targeted disruption of the p50 subunit of NFκB leads to multifocal defects in immune response. Cell 1995;80:321-340.
21. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Rysek R, Lira SA, et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NFκB/Rel family. Cell 1995;80:331-340.
22. Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, Gerondakis S. Mice lacking the c-rel proto-oncogene exhibit defects in lymphcyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995;9:1965-1977.
23. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, et al. Expression of relb is required for the development of thymic medulla and dendritic cells. Nature 1995;373:531-536.
24. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
25. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor a gene in primary macrophages. J Exp Med 1990;171:35-47.
26. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM. Regulation of interleukin-12 p40 expression through an NF-κB half-site. Mol Cell Biol 1995;15:5258-5267.
27. Tone M, Thompson SA, Tone Y, Fairchild PJ, Waldmann H. Regulation of IL-18 (IFN-γ-inducing factor) gene expression. J Immunol 1997;159:6159-6163.
28. Takeuchi M, Okura T, Mori T, Akita K, Ohta T, Ikeda M, Ikegami H, et al. Intercellular production of interleukin-18 in human epithelial-like cell lines is enhanced by hyperosmotic stress in vitro. Cell Tissue Res 1999;297:467-473.
29. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive for TLR4 as the lps gene product. J Immunol 1999;162:3749-3752.
30. O'Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily : crucial receptors for inflammation and host defense. Immunol Today 2000;21:206-209.
31. Zhang FX, Kirschning CJ, Macinelli R, Xu XP, Jin Y, Faure E, Mantovani A, et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999;267:2605-2609.
32. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, et al. In vivo transduction of cis element decoy against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 1997;3:894-899.
33. Yamada T, Horiuchi M, Morishita R, Zhang L, Pratt RE, Dzau VJ. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. J Clin Invest 1995;96:1230-1237.
34. Morishita R, Higaki J, Tomita N, Aoki M, Moriguchi A, Tamura K, Murakami K, et al. Role of transcriptional cis-elements, angiotensinogen geneactivating element, of angiotensinogen gene in blood pressure regulation. Hypertension 1996;27:502-507.
35. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995;92:5855-5859.
36. Tsutsui H, Mizoguchi Y, Morisawa S. Importance of direct hepatocytolysis by liver macrophages in experimental fulminant hepatitis. Hepatogastroenterology 1992;39:553-559.
37. Myers KJ, Eppihimer MJ, Hall L, Wolitzky B. Interleukin-12-induced adhesion molecule expression in murine liver. Am J Pathol 1998;152:457-468.
38. Chomczynski P, Sacchi L. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
39. Svetic A, Finkelman FD, Jain YC, Dieffenbach CW, Scott DE, McCarthy KF, Steinberg AD, et al. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol 1991;147:2391-2397.
40. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y, Kaneda K. Interferon-γ-inducing factor upregulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996;157:3967-3973.
41. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
42. Muto Y, Nouri-Aria K, Meager A, Alexander G, Eddleston A, Williams R. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988;2:72-74.
43. Streetz K, Leifeld L, Grundman D, Ramakers J, Eckert K, Spengler U, Brenner D, et al. Tumor necrosis factor α in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000;119:446-460.
44. Ruetten H, Thiemermann C. Combination immunotherapy which neutralizes the effects of TNF-α and IL-1β attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. J Physiol Pharmacol 1997;48:605-621.
45. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular disease. Proc Natl Acad Sci U S A 1996;93:11421-11425.
46. Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and space Disse. HEPATOLOGY 1985;5:683-692.
47. Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 2000;174:192-209.
48. Tsuji H, Mukaida N, Harada A, Kaneko S, Matsushita E, Nakanuma Y, Tsutsui H, et al. Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-γ deficient mice by a concomitant reduction of TNF-α, IL-12, and IL-18 production. J Immunol 1999;162:1049-1055.
49. Matsui K, Yoshimoto T, Tsutsui H, Hyodo Y, Hayashi N, Hiroishi K, Kawada N, et al. Propionibacterium acnes treatment diminishes CD4+NK1.1 + T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 1997;159:97-106.
50. Essani NA, McGuire GM, Manning A, Jaeschke H. Differential induction of mRNA for ICAM-1 and selections in hepatocytes, Kupffer cells and endothelial cells during endotoxemia. Biochem Biophys Res Commun 1995;211:74-82.
51. Begg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF kappa B. Nature 1995;376:167-170.
52. Iimuro Y, Nishimura T, Hellerbrand C, Behrns KE, Schoonhoven R, Grisham J, Brenner DA. NFκB prevents apoptosis and liver dysfunction during liver regeneration. J Clin Invest 1998;101:802-811.